CBD and Menopause | Clinical Research

CBD and Menopause – Help us investigate 

We would like to hear from individuals based in the UK or Ireland who are already taking CBD for menopause (usually in the form of oil or spray), what dose they are taking and what results they are finding (benefits, improvements or other effects).

We would also like to offer a significant discount to perimenopausal or menopausal women who would like to try our advanced Satipharm CBD capsules who are willing to share their experiences with us.

Once we get this first set of feedback, we can build an understanding of the impact CBD is having on the symptoms and design an appropriate Phase 2 clinical trial.

To express your interest in trying Satipharm CBD and sharing your experiences and symptom relief or participating in the phase 2 trial when this commences, please click on the link below and complete the questionnaire. We will then be in touch via email. 

Take The Survey

What is Perimenopause and Menopause?

Perimenopause for most women starts between the ages of 42 – 52. Perimenopause refers to the transition period prior to menopause (medically defined as when there has been no menstrual bleeding for 12 months).

What are the symptoms of perimenopause and menopause?

Perimenopause is characterised by changes in the levels of the hormones oestrogen and follicle-stimulating hormone (FSH).  This can cause several symptoms, including:

  • Irregular menstrual cycles
  • Hot flashes
  • Night sweats
  • Fatigue
  • Sleep issues
  • Mood swings

What is CBD?

CBD, which is short for cannabidiol, is a cannabinoid - a chemical found naturally in the cannabis and hemp plants. CBD differs from another commonly-known cannabinoid THC (tetrahydrocannabinol) in that it is non-intoxicating and does not induce the “high” typically associated with cannabis use.

The CBD in Satipharm capsules is a natural chemical compound harvested from hemp plants. 

The World Health Organisation has declared CBD to have ‘a good safety profile…and there is no evidence of any public health related problems associated with the use of CBD’.

How could CBD help with Perimenopause and Menopause?

There has been increasing feedback on CBD in alleviating some of the symptoms of perimenopause and menopause, via its interaction with the body’s endocannabinoid system (ECS).

The endocannabinoid system refers to a collection of cell receptors, called cannabinoid receptors, which are present in the brain, organs, and other tissues throughout the body. The endocannabinoid system works by interacting with chemical messengers, including CBD.

Research indicates that this system plays an essential role in many bodily functions and other aspects of health, including:

  • mood regulation
  • immune functions
  • pain
  • sleep
  • memory
  • fertility and reproduction
  • temperature regulation

Menopause appears to disrupt the endocannabinoid system, and there are cannabinoid receptors throughout the female reproductive system, so it is possible that CBD could reduce some of the symptoms relating to menopause.

The TV presenter and host of Loose Women, Andrea McLean, already takes CBD for her menopause symptoms - “It has ­massively taken the edge off things with the flushes and it has made me less ­anxious because anxiety is still a key thing for me.’’

The North American Menopause Society reviewed the evidence on alternative approaches to treating the symptoms of menopause, and found limited benefit from certain approaches, such as exercise, yoga, massage, meditation, amongst others. They also determined that there were insufficient clinical trial results to support the use of soy, black cohosh or vitamin E in alleviation of symptoms.

However, CBD has already been widely reported in the media to improve sleep, anxiety, reduce inflammation and provide benefits for numerous other symptoms, and anecdotal evidence is now building that demonstrates CBD provides these and other supportive properties during perimenopause and menopause.

Help us with our Clinical Trial

The team here at Satipharm have already conducted phase 1 clinical trials to prove that our Advanced Gelpell® formulation is much more effective* at reaching the body than either CBD oil or sprays.

We have also shown in a phase 2 clinical trial that our CBD Gelpell® significantly reduce seizures in children with refractory epilepsy by an average of 73%.

We are now turning our sights on perimenopause and menopause, with the aim that our advanced CBD formulation will provide significant benefits for some of these symptoms.

If you are already taking CBD and are willing to share your story to help us progress our research, then please click the link below. As a thank you, we are offering a significant discount to perimenopausal or menopausal women who would like to try our advanced Satipharm CBD capsules and share their experience.

Once we analyse this feedback, we can build a better understanding of the impact CBD is having on the symptoms and design the appropriate Phase 2 clinical trial to support these initial reports.

Take The Survey


Stanford Professor and national steering committee chair of the Women's Health Initiative, Marcia Stefanick, PhD, speaking at the Womens Health Forum, Stanford: https://www.youtube.com/watch?v=b_3uHcnXO4k&t=5s

Pubmed.gov https://www.ncbi.nlm.nih.gov/pubmed/14716179

Please note:

This is a research study only and is not intended to promote the use of Satipharm CBD Gelpell® capsules for any medical condition.